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Objectives
Phase II trial to evaluate dosing and interval range, prelim-
inary efficacy, safety, immunogenicity, and pharmacoki-
netics of subcutaneous (s.c.) canakinumab in patients
with active sJIA.
Methods
19 children 4–19 years old, with fever, at least 2 active
joints, CRP > 50 mg/L and steroids ≤0.4 mg/kg, were
enrolled in an open label, staggered dose escalation study.
Patients received a single sc injection of canakinumab in
the dose range 0.5–9 mg/kg, followed by an observation
period and re-dosing upon relapse. Dose escalation was
based on safety and efficacy review of each cohort.
Response was measured according to modified ACR pedi-
atric criteria, (at least 3/6 variables improved by ≥30%
with no more than one variable worsening by >30% and
no fever). Relapse was defined as reappearance of fever
and CRP > 30 mg/L, and/or ACR pediatric flare criteria.
Results
11/19 patients responded to canakinumab. At Day 15
post first dose all the 11 responders achieved at least an
ACR pediatric 50. In 4 cases inactive disease status was
reached (no joints with active arthritis, no fever, normal
CRP and no disease activity according to physician's
assessment). Time to relapse after first dose ranged from
23 days to >200 days. The injections were well tolerated
and no immunogenicity developed. One serious adverse
event (gastritis with ulcer bleeding) was reported.
Conclusion
In this dose-escalation trial canakinumab was efficacious
and provided improvement in sign and symptoms of sJIA
with an acceptable safety profile.
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